The major focus of my clinical and research career has been to improve the clinical care and quality of life for all older adults from diverse backgrounds and their family caregivers who are dealing with cognitive and affective disorders in order to initiate early intervention, alleviate psychosocial burden on the patient and family, and reduce the impact of race, language, culture and class on the delivery of health services and their subsequent health outcomes. My wife and her family are from the West Indies (Antigua) and I have spent the better part of our two decades of marriage fighting to ensure my mother in-law (Alzheimer’s disease) and father-in-law (multiple strokes) get the respect and medical care that they deserve, even if they are unwilling or unable to stand up for themselves. I also witnessed the struggles my grandmother faced caring for my grandfather’s dementia, including the lack of available caregiver support mechanisms. To me, the need to understand root causes of disease, provide strategies for early detection of disease that that will work in all older adults regardless of background, improve health outcomes while reducing healthcare costs, and do this in culturally-sensitive fashion is not just a professional activity, it is a personal battle. Throughout my career, I have been able to maintain continuous public and private funding to support my research efforts. My current research program focuses on four themes: (1) Developing and validating new clinical assessment scales to improve detection of cognitive impairment in multicultural community samples to improve health outcomes; (2) Studying the interaction between race/ethnicity, socioeconomic status, and multiple chronic conditions on the risk of cognitive impairment; (3) Characterizing the clinical, cognitive, behavioral, and biomarker features of neurodegenerative disorders; and (4) Creating novel interventions aimed at risk reduction and dementia prevention. The founding principles of my research are the dual goals of promoting lifespan (living longer) and healthspan (living better). I pioneered dementia screening measures that offer quick, valid, reliable, and culturally sensitive assessments of older adults regardless of race, language, or education with collaborative projects in Ecuador, Argentina, Spain, Brazil, Taiwan, Singapore, Thailand, Korea, Czech Republic, and China, developed regression models characterizing the transition from healthy aging to dementia with inflection points in cognitive performance that occur 1-3 years before the clinical detection of cognitive impairment that guided selection of brief cognitive measurements sensitive to early decline for use in a screening program, characterized the older adults’ intention to consent to dementia screening using population-based methods, directed 50 AD clinical trials, helped pioneer MRI and CSF biomarkers of dementia, characterized the diagnostic experience of family caregivers getting a diagnosis for their loved ones, and studied caregiver burden, anticipatory grief and well-being to develop interventions that benefit the patient and family alike. In prior positions at Washington University and NYU, I served as Leader of the Outreach, Recruitment, and Education Cores for NIA-funded Alzheimer Disease Centers, developing protocols to improve the research recruitment and retention of older adults from multicultural backgrounds, interprofessional education programs, and dissemination of research findings back to the community. As part of the current R01, I obtained an Administrative Supplement from the National Library of Medicine to create an open-access database for other investigators to benefit from this rich multicultural cohort, and am co-investigator on three R01s from my former mentees on their paths to research independence. I have successfully led translational research projects characterizing the clinical, cognitive, biochemical and pathological basis of dementias resulting in 214 peer-reviewed publications and 28 book chapters in leading textbooks in Geriatrics, Neurology and Psychiatry. During this funding cycle, we have published 42 peer-reviewed papers using R01 data and methods and 15 book chapters. I have had the opportunity to demonstrate personal and professional growth and leadership in multi-component program projects and center grants as an investigator, Associate Core Leader, Satellite Leader, Core Leader, and Associate Director of NIH-funded P01, P30 and P50 Centers. My expertise, scientific productivity, and leadership in brain aging, cognitive health, neurodegenerative disease and health disparities qualify me to be the PI of this innovative project.

Grants Awarded

7R01AG040211-06, Galvin (PI), 9/30/11-5/31/18              

Multicultural Community Dementia Screening

The major goals of this project are to provide cross-cultural validation of dementia screening methods and biological validation against imaging and CSF biomarkers of Alzheimer disease and related disorders. Role: PI


5U01NS100610-02, Leverenz (PI), 9/30/16-9/29/21

Dementia with Lewy Bodies Consortium

The major goals of this project is to develop a national network to study Dementia with Lewy bodies including longitudinal clinical and cognitive characterization, imaging and CSF biomarkers, and autopsy. Role: Site PI


1R01AG056610-01, Brody (PI), 8/1/17-3/31/22

A Multi-Site Cluster RCT of the Dementia Symptom Management at Home Program

The major goal of this project is to conduct a randomized trial of the Dementia Symptom Management at Home Program for efficacy in improving quality of care for persons living with dementia and their informal caregivers receiving home healthcare. Role: Site PI


1R01AG054425-01A1, Boltz (PI), 5/1/17-4/30/22

Reducing Disability via a Family-centered Intervention for Acutely-Ill Persons with Alzheimer’s disease and Related Dementias

The major goals of this project are to test and validate a family-centered function focused care (Fam-FFC) plan to improve physical function, cognitive function, and medicoeconomic outcomes in hospitalized patients with dementia.  Role: Co-Investigator


5R01NS088040-04, Fieremans/Novikov (PIs), 9/1/14-7/31/19     

Mesoscopic Biomarkers of Neurodegeneration with Diffusion MRI

The major goals of this project are to distinguish and quantify the different underlying white matter pathological processes in vivo by means of magnetic resonance imaging (MRI). Role: Co-Investigator


5R01AG052510-02,  Lyketsos (PI), 9/30/16-5/31/21              

Escitalopram for Agitation in Alzheimer’s Disease

The major goals of this project is conduct a randomized double-blind, placebo controlled trial of Escitalopram to reduce agitation and aggression in patients with moderate to severe Alzheimer’s disease. Role: Site PI


Harry T. Mangurian Foundation Investigator Initiated Award, Galvin (PI), 9/1/17-8/31/19

The Dementia Prevention Initiative

The major goal of this project is to develop a dementia prevention initiative using a precision medicine approach with personalized tailored interventions in deeply phenotyped individuals. Role: PI


Leo and Anne Albert Charitable Trust Investigator Initiated Award, Galvin (PI), 10/1/17-9/30/20

Dementia Prevention Program

The major goal of this project is to support the development of ancillary studies to increase deep phenotyping of individuals participating in prevention research protocols. Role: PI


Anonymous Foundation Investigator Initiated Award, Galvin (PI), 12/1/16-11/30/18            

Dementia Prevention Initiative

The major goal of this project is to develop the protocol to initiate a dementia prevention program. Role: PI


221AD302 Biogen, Chrisphonte (PI), 9/2/15-6/30/18

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease

Goals: The major goal of this clinical trial is to test whether the monoclonal antibody, Aducanumab can reduce brain amyloid and improve the symptoms of individuals with Alzheimer’s disease. Role: Co-PI


992FD001 Biogen, Galvin (PI), 4/19/17-6/30/19

A Study to Model Rates of Change on Neuropsychological Test Measures in Subjects Diagnosed with Behavioral Variant Frontotemporal Dementia and Healthy Subjects

Goals: The major goal of this Phase 0 study is to develop the instruments necessary to conduct a RCT in patients with behavioral variant Frontotemporal Degeneration. Role: PI


The Michael J. Fox Foundation, Galvin (PI), 3/9/18-3/8/19


Goals: The major goals of this study is to characterize the role of LRRK2 mutation in the onset and progression of Parkinson’s disease. Role: PI


CAPI015A2201J Novartis, Galvin (PI), 10/18/17-6/30/18

A randomized, double-blind, placebo-controlled, two cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s

Goals: The major goals of this clinical trial is to conduct a test of two agents, a BACE inhibitor and an active vaccine in the prevention of Alzheimer’s disease in individuals who are ApoE4 homozygotes. Role: PI

Recent Publications

Last 2 years

In Press

  1. Granic A, Mossop H, Engstrom G, Davies K, Dodds R, Galvin JE,  Ouslander JG, Tappen R, Sayer AA. Factors associated with physical performance measures in a multi-ethnic cohort of older adults. Gerontol Geriatr Med In Press 2018
  2. Tolea MI, Chrisphonte S, Galvin JE. Sarcopenic obesity and cognitive performance. Clin Interv Aging In Press 2018.
  3. Goldman JG, Vernaleo B, Camicioli R, Dahodwala N, Dobkin RD, Ellis T, Galvin JE, Marras C, Edwards J, Fileds J, Golden R, Karalwish J, Levin B, Shulman L, Smith G, Tangney C, Thomas CA, Troster AI, Uc EY, Coyan N, Ellman C, Ellman M, Hoffman C, Hoffman S, Simmonds C.  Cognitive impairment in Parkinson’s disease: A report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health.  Nat Parkinson J In Press 2018.
  4. Galvin JE. Advancing personalized treatment of Alzheimer’s disease: A call for the N-of-1 trial design.  Future Neurology In Press 2018



  1. Hamed M, Schrami F, Wilson J, Galvin JE, Sabbagh MN. Occipital and Cingulate Hypometabolism are significantly underreported on 18-Fluorodeoxyglucose positron emission tomography scans of patients with Lewy body dementia. J Alzheimers Dis Parkinsonism 2018;8:428.
  2. Tolea MI, Galvin JE. The genetics of dementia with Lewy bodies. Hanb Clin Neurol 2018; 148:431-440.
  3. Galvin JE. Using informant and performance screening methods to detect mild cognitive impairment and dementia. Curr Rep Gerontol 2018; 7:19-25
  4. Galvin JE, Howard DH, Denny SS, Dickinson S, Tatton N. The Social and Economic Burden of Frontotemporal Degeneration. Neurology 2017 89:2049-2056. (PMCID:5711509)
  5. Galvin JE. The Prevention of Alzheimer’s Disease: Lessons Learned and Applied. J Am Geriatr Soc 2017 65:2128-2133.
  6. Berman SE, Koscik RL, Clark LR, Mueller KD, Bluder L, Galvin JE, Johnson SC. Use of the Quick Dementia Rating System (QDRS) in the Wisconsin Registry for Alzheimer’s Prevention. J Alz Dis Report 1:9-13; 2017. (PMCID: 5557032)
  7. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin JE, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K.. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 89:88-100; 2017 (PMCID: 5496518).
  8. Read KB, Lapolla FWZ, Tolea MI, Galvin JE, Surkis A.  Improving Data Collection, Documentation, and Workflow in a Dementia Screening Study. J Med Libr Assoc April 2017; 105:160-166. (PMCID: 5370608).
  9. Ryu HJ, Kim M, Moon Y, Choi Y, Han J, Galvin JE, Han SH. Validation of the Korean Version of the Lewy Body Composite Risk Score (K-LBCRS). J Alzheimers Dis. 2017; 55:1395-1401.
  10. Boeve BF, Dickson DW, Duda JE, Ferman TJ, Galasko DR, Galvin JE, Goldman JG, Growdon JH, Hurtig HI, Kaufer D, Kantarci K, Leverenz JB, Lippa CF, Lopez OL, McKeith IG, Singleton AB, Taylor A, Tsuang D, Weintraub D, Zabetian CP. Arguing against the proposed definition changes of PD. Movement Disord 2016; 31:1619-1622 (PMCID: 5168716)
  11. Tolea MI, Galvin JE. The relationship between mobility dysfunction staging and global cognitive performance. Alz Dis Assoc Disord, 2016; 30:230-236 (PMCID: 4970960)
  12. Brody AA, Guan C, Cortes T, Galvin JE.  Development and testing of the Dementia Symptom Management at Home (DSM-H) Program: An interprofessional home healthcare intervention to improve quality of life for persons with dementia and their caregivers. Geriatr Nurs, 37:200-206, 2016.
  13. Kelleher M, Tolea MI, Galvin JE. Anosognosia increases caregiver burden in mild cognitive impairment. Int J Geriatr Psych, 31:799-808, 2016.
  14. Johnson DK, Langford Z, Garnier M, Storandt M, Morris JC, Galvin JE. Onset of Mild Cognitive Impairment in Parkinson’s Disease Alz Dis Assoc Disord 2016; 30:127-133 (PMCID: 4592684)

Invited Book Chapters:

  1. Sheik M, Galvin JE. Neurocognitive Disorders with Lewy Bodies: Lewy Body Dementia and Parkinson’s Disease. In: TEXTBOOK OF NEUROPSYCHIATRY AND BEHAVIORAL NEUROSCIENCES. Yudofsky SC, Hales RE, Arciniegas DB (Eds). American Psychiatry Publishing Inc,  In press 2018
  2. Galvin JE. Neurological Signs in Old Age.  In: BROCKLEHURST’S TEXTBOOK OF GERIATRICS AND CLINICAL GERONTOLOGY, 8TH EDITION. Fillit H, Rockwood K, Young JB (Eds) Elsevier, Philadelphia, PA, In Press, 2018.
  3. Galvin JE. Mental Status and Neurologic Examination. In: HAZZARD’S PRINCIPLES OF GERIATRIC MEDICINE AND GERONTOLOGY, 7TH EDITION. Halter JB, Asthana,S, High K, Studenski S, Ouslander J, Tinetti, M (Eds). McGraw-Hill, New York, NY. In Press 2018.
  4. Tolea MI, Galvin JE.  Treatment of Mild Cognitive Impairment. In: EVIDENCE-BASED DEMENTIA PRACTICE, 2ND EDITION. Qizilbash N, Brodaty H, Erkinjuntti T, Foster N, Sano M, Lopez Arrieta J, Bullock R (Eds). Wiley Press, New York, NY, In Press 2018.
  5. Galvin JE, Goodyear M. Brief Informant Interviews to Screen for Dementia. The AD8 and Quick Dementia Rating System. In: COGNITIVE SCREENING INSTRUMENTS. A PRACTICAL APPROACH – 2ND EDITION. Larner AJ (Ed) Springer Press, 2017.
  6. Galvin JE. Detection of Dementia. In: DEMENTIA CARE: AN EVIDENCE BASED APPROACH. Boltz M, Galvin JE (Eds). Springer, New York, NY. Pp 33-45; 2016


2018 Heroes in Medicine: Healthcare Innovation, Palm Beach Medical Society


  • New York University, New York, NY - BA (Chemistry)
  • Rutgers University, New Brunswick, NJ - MS (Nutrition)
  • UMDNJ-NJ Medical School, Newark, NJ - MD
  • Saint Louis University, St Louis, MO - MPH (Epidemiology)